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Abstract: Following rabies virus (RABV) exposure, a combination of thorough wound washing,
multiple-dose vaccine administration and the local infiltration of rabies immune globulin
(RIG) are essential components of modern post-exposure prophylaxis (PEP). Although modern
cell-culture-based rabies vaccines are increasingly used in many countries, RIG is much less available.
The prohibitive cost of polyclonal serum RIG products has prompted a search for alternatives and
design of anti-RABV monoclonal antibodies (MAbs) that can be manufactured on a large scale with
a consistent potency and lower production costs. Robust in vitro neutralization activity has been
demonstrated for the CL184 MAb cocktail, a 1:1 protein mixture of two human anti-RABV MAbs
(CR57/CR4098), against a large panel of RABV isolates. In this study, we used a hamster model
to evaluate the efficacy of experimental PEP against a lethal challenge. Various doses of CL184
and commercial rabies vaccine were assessed for the ability to protect against lethal infection with
representatives of four distinct bat RABV lineages of public health relevance: silver-haired bat (Ln
RABV); western canyon bat (Ph RABV); big brown bat (Ef-w1 RABV) and Mexican free-tailed bat
RABV (Tb RABV). 42–100% of animals survived bat RABV infection when CL184 (in combination with
the vaccine) was administered. A dose-response relationship was observed with decreasing doses of
CL184 resulting in increasing mortality. Importantly, CL184 was highly effective in neutralizing and
clearing Ph RABV in vivo, even though CR4098 does not neutralize this virus in vitro. By comparison,
19–95% survivorship was observed if human RIG (20 IU/kg) and vaccine were used following
challenge with different bat viruses. Based on our results, CL184 represents an efficacious alternative
for RIG. Both large-scale and lower cost production could ensure better availability and affordability
of this critical life-saving biologic in rabies enzootic countries and as such, significantly contribute to
the reduction of human rabies deaths globally.
Keywords: bat viral diseases; monoclonal antibody; immune globulin; lyssavirus; post-exposure
prophylaxis; rabies; vaccine; zoonosis

1. Introduction
Rabies is an acute progressive encephalitis caused by lyssaviruses. Despite significant progress
in our understanding of rabies pathobiology and epidemiology, and major advancements in the
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development of safe and effective biologics for disease prevention, this neglected zoonosis causes
approximately 60,000 human deaths annually [1,2]. Although dogs are the major global reservoir for
rabies virus (RABV), bats are responsible for the majority of human rabies fatalities in the Americas,
Australia and Western and Central Europe. Regardless of the source of viral exposure, human rabies is
preventable with proper wound care, prompt administration of modern vaccine and rabies immune
globulin (RIG) [3,4]. Over the past several decades, post-exposure prophylaxis (PEP) schedules have
evolved, encompassing fewer doses of both intramuscular (i.m.) as well as dose-sparing intradermal
(i.d.) routes for administration of inactivated vaccine in as few as four doses. However, in the absence
of licensed, commercially available, live-attenuated rabies vaccines, administration of RIG remains a
critical component of PEP when inactivated vaccines are used [3,5].
Current commercially available human and equine RIGs (HRIG, ERIG) are produced via pooling
of human or equine plasma from immunized donors. Such production processes are associated with
significant costs as well as with a possibility for transmission of potential bloodborne pathogens.
Low-scale manufacturing, coupled with prohibitive cost, renders these immune globulins virtually
unavailable for a majority of the population at risk in rabies-enzootic countries such as Asia and Africa,
where the demand is the highest. New approaches, such as the use of hybridoma and humanization
technologies, as well as use of single chain and VHH single domain antibodies, allow for cell culture
or microbial expression systems production of monoclonal antibodies (MAbs), a promising alternative
to polyclonal RIG with reduced risks for transmission of pathogens and large-scale production for a
reduced cost. An inherent disadvantage of any MAb, however, is the specificity/affinity to a single
binding epitope on a viral protein and consequently a diminished breadth of neutralizing activity for
certain virus variants with amino acid substitutions that prevent MAb binding [5,6].
The concept of using a cocktail of at least two MAbs, which target distinct, non-overlapping
epitopes and that do not compete for binding to the RABV glycoprotein, as a potential alternative to
RIG in PEP, has been widely accepted by the scientific community and also endorsed by WHO [3,7–10].
CL184 is a cocktail of two human MAbs (CR57 and CR4098), produced in human PER.C6® cells.
CL184 meets the criteria of binding to different epitopes (CR57 to epitope I, CR4098 to IIIa) and does
not engender competition for the binding to RABV glycoprotein [8,11]. Previously, CR57, CR4098
and CL184 were evaluated in vitro against a panel of 26 distinct RABV isolates of public health and
veterinary significance [12]. Although CR57 alone did not neutralize a south central skunk RABV and
big brown bat RABV (Eptesicus fuscus western lineage 1, Ef-w1); and CR4098 alone did not neutralize
mongoose RABV from South Africa, big brown bat RABV (Eptesicus fuscus eastern lineage 1, Ef–e1)
or western canyon bat (Parastrellus hesperus from Arizona) [8], it was shown that the combination
of these two MAbs, CL184, did provide neutralization of all 26 tested RABV isolates [12], as well
as neutralization of an additional panel of 18 RABV isolates (reported in this manuscript, Table 1).
Furthermore, it was shown retrospectively that the lack of neutralization was related to epitope
mutations introduced during cell culture amplification of the primary RABV isolates in the case of
the south-central skunk RABV and the western canyon bat (Ph) RABV from Arizona (previously
unpublished results). During one in vivo experiment, CL184, in combination with vaccine, protected
hamsters against a lethal challenge with canine RABV, when administered 24 h after exposure, which
was comparable with the results obtained for HRIG. In addition, CL184 was similar to HRIG in
demonstrating a lack of interaction with vaccine [12]. These results suggested that CL184 could be an
efficacious alternative to RIG as a part of rabies PEP.
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Table 1. Breadth of in vitro neutralization of HRIG, CL184 and its components against selected RABV
isolates not covered by previous publications [12].
Lyssaviruses

HRIG *

CR57

CR4098

CL184

Cow/dog, Sri Lanka
Dog, China 2005
Dog, China (RV342)
Dog, India (I 148)
Dog, India (I 151)
Dog, India (I 155)
Dog, Philippines
Dog, Philippines (231/002)
Dog, Tunisia
Human/dog, UK ex India
Human/wolf, Russia Siberia (RVHN)
Mongoose, South Africa
Raccoon dog, Russia/Far East
Skunk, south central (SK4384)
Bat, Lasiurus borealis, TN (tn132)
Bat, Lasiurus borealis, TN (tn269)
Bat, Lasiurus borealis, VA (VA399)
Bat, Lasiurus cinereus, TN

+
+
+
NT
+
+
+
+
+
NT
+
+
+
+
NT
NT
NT
NT

+
+
+
NT
+
+
+
+
+
NT
+
+
+
+
NT
NT
NT
NT

+
+
+
NT
+
+
+
+
+
NT
+
+
+
NT
NT
NT
NT

+
+
+
+
+
NT
+
NT
+
+
+
+
+
+
+
+
+
+

* Imogam (Sanofi Pasteur); + indicates neutralization; NT—not tested.

Given the public health importance and the diversity of bat RABV present in the Americas, as
well as the frequency and distribution of isolates with mutations in the MAb binding epitopes [13],
the objective of this study was to evaluate the efficacy of CL184 against selected distinct bat RABV
variants from North America (including those having a critical mutation in the MAb-binding site on
the viral glycoprotein). The work was done using an animal model to compare vaccine protection
using standard PEP (that included HRIG and commercial rabies vaccines) against those using CL184
in substitution for HRIG.
2. Materials and Methods
2.1. Animals and Viruses
Two-month-old female Syrian hamsters (Mesocricetus auratus), weighing approximately 100–120 g,
were obtained from commercial suppliers and held for acclimation for 3–7 days upon arrival before
use. Four different RABV isolates, representatives of distinct bat-associated RABV lineages (Figure 1),
were used as a challenge in PEP experiments. An Eptesicus fuscus Ef-w1 RABV (A09-2400L), 106.1 50%
mouse intracerebral lethal doses (MICLD50 )/50 µL, was isolated from the salivary glands of a naturally
infected gray fox (Urocyon cinereoargenteus) in Arizona. A Parastrellus hesperus RABV (Ph 3860 RABV,
A07-0449), 104 MICLD50 /50 µL, was isolated from the salivary glands of a naturally infected western
canyon bat from Arizona. A Lasionycteris noctivigans RABV (WA Ln RABV, A04-0723 and A12-6377),
106 MICLD50 /50 µL, was isolated from the salivary glands of a naturally infected silver-haired bat
from Washington. A Tadarida brasiliensis RABV (Tb RABV, A14-3368 and TX3368), approximately
105 TCID50 /100 µL, was isolated from the brain of a naturally infected Mexican free-tailed bat from
Texas. All the original isolates were amplified in cell culture or following i.c. challenge in mice.
The titer of viruses was determined in mouse neuroblastoma cell culture and expressed in the 50%
tissue culture infectious doses (TCID50 ) or focus forming units (FFU) as well as via titration in mice
(MICLD50 ) and relative pathogenicity was determined in naive Syrian hamsters prior to experimental
prophylaxis. Only RABV isolates that produced at least 75% mortality in this model were selected for
further experiments with a sample size determined accordingly. All animal handling and experimental
procedures were undertaken in compliance with CDC Institutional Animal Care and Use Committee
guidelines (protocols #1593FRAHAMC and 2266FRAHAMC).
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with protein purification techniques result in highly purified MAb devoid of other contaminants.
Hence, such antibodies can be accurately quantified and thus dosed on basis of µg/kg, thereby
excluding dosing variability as a result of inconsistency in potency measurements.
2.3. Experimental Design
The calculations of group sample sizes for each individual RABV isolate were based on statistical
analysis and taking into account the mortality of naïve (non-treated) hamsters during preliminary
experiments. To achieve the statistical power required to demonstrate the potential added benefit of
tested biologics, we selected a cutoff in mortality of ≥75%. If mortality was 100% in RABV-challenged
hamsters (via a titration experiment), a group size of 12 animals was considered adequate and selected
for consequent experiments. If, however, the mortality of naïve animals was <100% but >75%, a group
size of 21 animals was selected as adequate for comparative non-inferiority non-clinical experiments.
2.4. Model Validation/Post-Exposure Prophylaxis (PEP) Initiation Determination
Prior to the evaluation of PEP efficacy, determination of the PEP initiation window was conducted.
Approximately two-month-old female Syrian hamsters (n = 12 or 21) were assigned randomly to
experimental groups and infected into the left gastrocnemius muscle with an expected lethal dose of
RABV (Ef-w1 RABV, Ph 3860, WA Ln, Tb RABV, based upon prior observations; unpublished data).
Thereafter, PEP was initiated 2, 6 or 24 h following the challenge. On days 0 (set as the day of PEP
initiation), 3, 7, 14, +/− 28 the animals received a dose of rabies vaccine (HDCV for Ef-w1, Ph and
WA Ln; and PCECV for Tb) applied into the right gastrocnemius muscle. In addition, HRIG at a dose
of 20 IU/kg was administered at the initiation of PEP into the same i.m. location as virus challenge.
For comparison, besides a control (PBS only) group, a vaccine-only group was included with the same
time windows of PEP initiation. Monitoring was the same as below for efficacy experiments.
2.5. Evaluation of the Efficacy of HRIG/Vaccine versus CL184/Vaccine during PEP
Female Syrian hamsters (n = 12 or 21) were assigned randomly to experimental groups and
infected in the left gastrocnemius muscle with a lethal dose of RABV. Timeline for challenge and
initiation of PEP, as well as viral dose used, were selected based on the model validation experiments
and prior experimental data regarding particular virus pathobiology in hamster model. The PEP was
initiated 24 h (Ln, Ph and Ef-w1 RABV) or 2 h post infection (p.i.) (Tb RABV). On days 0, 3, 7, 14, and
28 the animals received a dose of rabies vaccine. In addition, 50 µL of HRIG at 20 IU/kg or 50 µL of
different doses of CL184 at (6, 12 or 16 µg/kg for Ln, Ph and Ef-w1 RABV or 12, 18 and 24 µg/kg for
Tb RABV), were administered i.m. at the site of virus inoculation on day 0. The animals were followed
for 45 days and their clinical signs were monitored. All animals developing any specific signs of rabies
were euthanized immediately according to an IACUC approved clinical score. Brains were removed at
necropsy and subjected to detection of rabies virus antigens by the direct fluorescent antibody (DFA)
test, as described below. Similarly, all animals surviving at the end of the experimental period were
euthanized and their brains examined for the presence of RABV antigens.
2.6. Laboratory Methods
2.6.1. Direct Fluorescent Antibody (DFA) Test
The RABV antigens were detected in brain samples using the DFA test [14] with a
fluorescein-isothiocyanate (FITC)-conjugated anti-RABV MAb (Fujirebio Diagnostics, Inc., Malvern,
PA, USA).
2.6.2. Rapid Fluorescent Focus Inhibition Test (RFFIT)
The rapid fluorescent focus inhibition test (RFFIT) was performed according to a standard,
previously described protocol [15].

Trop. Med. Infect. Dis. 2017, 2, 48

6 of 12

2.6.3. Reverse Transcription Polymerase Chain Reaction (RT-PCR), Hemi-Nested RT-PCR (hnRT-PCR)
and Sequencing
To confirm identity of RABV in central nervous system (CNS) tissue of euthanized animals
with the initial inoculum and to identify any potential selection of escape mutations, total RNA was
extracted from the CNS tissue samples using TRIZol reagent (Ambion, Carlsbad, CA, USA) according
to the manufacturer’s recommendations. The RT-PCR was performed as described elsewhere [16]. The
RT-PCR products were purified and subjected to direct sequencing on an ABI 3730 DNA Sequencer
(Applied Biosystems, Carlsbad, CA, USA). The complete and partial nucleotide G gene sequences were
assembled and converted into amino acid sequences using the Bio Edit program, v.7 (Ibis Biosciences,
Carlsbad, CA, USA) [17]. Amino acid sequences of the aligned MAb binding epitopes were compared
across the dataset.
2.7. Statistical Analysis
Kaplan–Meier survival curves were calculated in the Statistical Analysis Software (SAS, version
9.2. SAS Institute Inc., Cary, NC, USA). The log-rank test was used to test differences between group
survival distributions. The null hypothesis of identical survival functions was rejected at p < 0.05.
GraphPad Prism, version 7 (GraphPad Software, La Jolla, CA, USA) was used to create survival
curve graphs.
3. Results
3.1. Neutralization of Selected RABV Isolates In Vitro
An additional set of 18 RABV isolates of public health importance from Africa, Asia and Americas
were tested for neutralization to complement the initial panel of 26 RABV isolates [12]. Twelve of the
isolates were tested with CR57, CR4098, and HRIG (Imogam), and all isolates were neutralized with
the exception of one, South Africa mongoose RABV, which was not neutralized by CR4098 (Table 1).
This RABV isolate contains a N336D mutation in its glycoprotein which explains the observed lack of
neutralization (data not shown). Further, 16 of 18 RABV isolates were tested and were shown to be
efficiently neutralized by CL184 (Table 1).
3.2. Model Validation/PEP Initiation Window
In the experiments dedicated to the determination of PEP initiation window, survivorship of
hamsters in control (placebo) groups was 8.3% for the Ln RABV, 0% for the Ph RABV, and 16.7%
for the Ef-w1 RABV challenge. In contrast, in the vaccine-only group with PEP initiated 6 h p.i. the
survivorship was 16.7%, 4.8%, 8.3%, whereas with PEP initiated 24 h p.i. it was 25%, 19%, 16.7% for
these viruses, respectively (Table 2, Figure 2).
When HRIG + HDCV were administered 6 h p.i., 83.3%, 57% and 75% of experimental animals
survived in the Ln RABV, Ph RABV, Ef-w1 RABV groups, respectively. Similarly, 83.3%, 66.7% and
91.7% of animals survived challenge with the Ln RABV, Ph RABV and Ef-w1 RABV, respectively, when
HRIG and vaccine were administered 24 h p.i.
In the experiment with the Tb RABV, 0% survivorship was observed in the control as well as in
the vaccine-only and in the HRIG + PCECV groups when biologics were administered 2 h p.i. (Table 2,
Figure 2).
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Table 2. Validation of animal model and postexposure prophylaxis (PEP) initiation (p-values based on
log-rank Mantel-Cox test, comparing CL184 with standard PEP regimen 20IU/kg HRIG/vaccine).
Survival after 45 days observation
Group

Ln (%)

p-Value *

Ph (%)

p-Value

Ef-w1 (%)

p-Value

Tb (%) ‡

p-Value

Control (PBS only)

8.3

-

0

-

16.7

-

0

-

Vaccine only, 6 h p.i.

16.7

0.9984

4.8

0.5224

8.3

0.0023

0

0.8619

Vaccine only, 24 h p.i.

25

0.5174

19

0.6200

16.7

0.3391

NA

HRIG/vaccine, 6 h p.i.

83.3

0.0002
0.0007

57

<0.0001
<0.0001

75

0.0005
0.0002

0

0.3901
0.3161

HRIG/vaccine, 24 h p.i.

83.3

<0.0001
0.0023

66.7

<0.0001
0.0002

91.7

<0.0001
0.0001

NA

-

* p-Value for vaccine-only group is comparison to control; HRIG/vaccine groups, first p-value is comparison to
control group and second is comparison to vaccine-only group. (Ph—Parastrellus hesperus, Ef-w1—Eptesicus fuscus
western
lineage
Ln—Lasionycteris
noctivagans, Tb—Tadarida brasiliensis North America). ‡ Groups challenged with
Trop. Med.
Infect.
Dis.1,2017,
2, 48
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Figure 2. Validation of model and PEP initiation—Kaplan-Meier survival curves for Syrian hamsters
Figure
2. Validation
ofrabies
modelviruses.
and PEP
initiation—Kaplan-Meier
survival
curves
forthe
Syrian
hamsters
after
infection
with bat
Hamsters
(n = 12 or 21 per group)
infected
with
indicated
after infection
bathrabies
viruses.
Hamsters
(n = 12
orconsisting
21 per group)
infected
with
the
indicated
RABV
isolate 2, with
6, or 24
prior to
intervention,
received
PEP
of either
vaccine
only
(HDCV
RABV
isolate
2,
6,
or
24
h
prior
to
intervention,
received
PEP
consisting
of
either
vaccine
only
(HDCV
or PCECV) or vaccine in combination with 20 IU/kg HRIG.
or PCECV) or vaccine in combination with 20 IU/kg HRIG.

3.3. Evaluation of the Efficacy of HRIG/Vaccine versus CL184/Vaccine during PEP
Table 2. Validation of animal model and postexposure prophylaxis (PEP) initiation (p-values based

In
experimental
evaluation
of the efficacy
of biologics
administered
24 HRIG/vaccine).
h p.i., Ln RABV,
onthe
log-rank
Mantel-Cox
test, comparing
CL184 with
standardwhen
PEP regimen
20IU/kg
HRIG (20 IU/kg) + rabies vaccine (HDCV) resulted in 58% survival, whereas survival of animals
Survival
after
days observation
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µg/kg
of 45
CL184,
42%, 50% and 67% survived,
Group
Ln (%)
p-Value *
Ph (%)
p-Value
Ef-w1 (%)
p-Value
Tb (%) ‡
p-Value
respectively (Table 3, Figure 3). In a mock-control group and in the vaccine-only group, 11% and 25%
Control (PBS only)
8.3
0
16.7
0
of experimental
respectively,
survived4.8
the challenge.
Vaccine only, 6animals,
h p.i.
16.7
0.9984
0.5224
8.3
0.0023
0
0.8619
In theonly,
experiment
RABV isolate
used, administration
of HRIG (20
Vaccine
24 h p.i. where
25 a Ph0.5174
19 was0.6200
16.7
0.3391
NA IU/kg) +
HDCV resulted in 19% survival whereas
groups treated with 60.0005
µg/kg, 12 µg/kg and
0.0002 survival in <0.0001
0.3901
HRIG/vaccine, 6 h p.i.
83.3
57
75
0
0.0007
0.0002
0.3161
16 µg/kg of CL184 was 57%, 48% and
57%, respectively<0.0001
(Table 4, Figure 3). In contrast,
survivorship
of
<0.0001
<0.0001
<0.0001
17%
and
0%
was
observed
in
the
mock-control
and
in
the
vaccine-only
group,
respectively,
following
HRIG/vaccine, 24 h p.i.
83.3
66.7
91.7
NA
0.0001
0.0023
0.0002
Ph RABV challenge.
* p-Value for vaccine-only group is comparison to control; HRIG/vaccine groups, first p-value is
comparison to control group and second is comparison to vaccine-only group. (Ph—Parastrellus
hesperus, Ef-w1—Eptesicus fuscus western lineage 1, Ln—Lasionycteris noctivagans, Tb—Tadarida
brasiliensis North America). ‡ Groups challenged with Tb RABV were administered PEP at 2 h p.i. with
PCECV vaccine.

3.3. Evaluation of the Efficacy of HRIG/Vaccine Versus CL184/Vaccine During PEP

Trop. Med. Infect. Dis. 2017, 2, 48

8 of 12

Trop. Table
Med. Infect.
Dis. 2017, 2,of48the efficacy of CL184/vaccine during PEP (p-values based on log-rank Mantel8 of 12
3. Evaluation

Cox test, comparing CL184 with standard PEP regimen 20IU/kg HRIG/vaccine).
Table 3. Evaluation of the efficacy of CL184/vaccine
during
PEP
(p-values based on log-rank
Survival after
45 Days
Observation
Groups test, comparing
Ln (%) CL184
p-Value
* standard
Ph (%) PEP
p-Value
(%) HRIG/vaccine).
p-Value
Tb ‡ (%)
p-Value
Mantel-Cox
with
regimen Ef-w1
20 IU/kg
Control (PBS only)
Vaccine only
Groups
20 IU/kg HRIG/vaccine
Control (PBS only)

24 μg/kg CL184/vaccine
Vaccine only
18 μg/kg CL184/ vaccine
20 IU/kg HRIG/vaccine
16 μg/kg CL184/ vaccine
24 µg/kg
CL184/vaccine
12 μg/kg
CL184/
vaccine
18
µg/kg
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0.5951
57.1
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0.3173
NA
* p-Value
for vaccine
vaccine-only
is comparison
HRIG/vaccine
groups, first
is
12
µg/kg CL184/
50 group 0.8931
47.6 to control;
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Figure 3. Evaluation of the efficacy of CL184/vaccine during PEP—Kaplan-Meier survival curves for
Figure
Evaluation
ofinfection
the efficacy
ofbat
CL184/vaccine
during
PEP—Kaplan-Meier
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for
Syrian3.hamsters
after
with
rabies viruses.
Hamsters
(n = 12 or 21 per
group)curves
infected
Syrian
hamsters
after
infection
with
bat
rabies
viruses.
Hamsters
(n
=
12
or
21
per
group)
infected
with
with a RABV isolate 2 or 24 h prior to intervention received PEP as outlined in Materials and Methods.
aHamsters
RABV isolate
2 or2024IU/kg
h prior
to intervention
PEP
asor
outlined
in for
Materials
andand
Methods.
received
HRIG
or CL184 at areceived
dosage of
6, 12
16 µg/kg
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Ef-w1
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received
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CL184
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dosage
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Ln,
Ph
and
Ef-w1
RABV or CL184 at a dosage of 12, 18 and 24 µg/kg for the Tb RABV.
RABV or CL184 at a dosage of 12, 18 and 24 μg/kg for the Tb RABV.
Table 4. Bat RABV isolates used in the animal studies.

Combination of HRIG + HDCV resulted in 95% survivorship when administered 24 h p.i. with
Epitope
CR4098
Epitope
the Ef-w1 RABV
variant, whereas CR57
administration
of
6 μg/kg,
12 μg/kg CR57
and 16 μg/kgCR4098
of CL184, in
RABV Isolate
(330–338)
Neutralization
Neutralization
combination with HDCV, resulted in(226–231)
86%, 95% and 100%
survivorship,
respectively
(Figure 3). A
Bat, Lasionycteris
KLCGVP in the KSVRTWNEV
Yes groups,
survivorship
of 33%noctivagans
and 38% was observed
mock-control and inYes
the vaccine-only
Bat, Parastrellus hesperus
KLCGVP
KSVRTWNET *
Yes
No
§
respectively,
forfuscus
this w1
virus
(Table
3, Figure
3).
KLCGVP
Yes
Yes
Bat, Eptesicus
lineage
KSIRTWNEI ‡
Bat,PEP
Tadarida
brasiliensis
KLCGVS
KSVRTWNEI
Yes in the HRIG
Yes+ PCECV
When
was
initiated 2 h p.i. with
Tb RABV, 67%
of animals survived
3860 RABV
isolate used in our
has I338T
CR4098
epitopeof
precluding
by with
group,* Ph
whereas
administration
ofstudy
12 μg/kg,
16mutation
μg/kg in
and
24 μg/kg
CL184,itsinneutralization
combination
that particular MAb. We used this mutation (resulting from cell culture passage) as a model to test CL184 in vivo
PCECV
resulted
in
67%,
83%
and
100%
survivorship,
respectively
(Figure
3).
A
survivorship
of 0%
against virus which is not neutralized in vitro by one MAb from the cocktail. ‡ Although some naturally-occurring
Eptesicus
fuscus Ef isolates
have
N336D mutation
in the
site III precluding
and 8%
was observed
in the
mock-control
and
theantigenic
vaccine-only
group. neutralization of CR4098, we
have not had that particular isolate available for in vivo experiments. Our isolate with N336 was neutralized by
both CR57 and CR4098. § Isolated from gray fox, Urocyon cinereoargenteus.
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Combination of HRIG + HDCV resulted in 95% survivorship when administered 24 h p.i. with
the Ef-w1 RABV variant, whereas administration of 6 µg/kg, 12 µg/kg and 16 µg/kg of CL184,
in combination with HDCV, resulted in 86%, 95% and 100% survivorship, respectively (Figure 3).
A survivorship of 33% and 38% was observed in the mock-control and in the vaccine-only groups,
respectively, for this virus (Table 3, Figure 3).
When PEP was initiated 2 h p.i. with Tb RABV, 67% of animals survived in the HRIG + PCECV
group, whereas administration of 12 µg/kg, 16 µg/kg and 24 µg/kg of CL184, in combination with
PCECV resulted in 67%, 83% and 100% survivorship, respectively (Figure 3). A survivorship of 0%
and 8% was observed in the mock-control and the vaccine-only group.
3.4. Sequence Analyses of the Original Inoculum and Virus Detected in CNS of Experimental Animals
When G nucleotide sequences of the original Ph 3860 isolate and its cell culture passages were
compared to each other, it was confirmed that the first cell culture passage contained a mix of two
variants, I338 and T338 (within the CR4098 binding epitope) and that consensus sequences of viral
populations from further cell culture passages demonstrated solely the T338 variant. Virus recovered
from the infected hamsters (following experimental challenge) resulted in a detection of either I338, or
T338, or both phenotypes irrespective of biologics used in PEP and in the mock-control groups. All
other output viruses matched the input virus demonstrating CL184 did not select for escape mutations.
Phylogenetic relationship of Ph 3860 as well as other bat RABV isolates used in this study to other
relevant bat RABV viruses is depicted in Figure 1 and relevant epitopes for virus variants used in this
experiment are shown in Table 4.
4. Discussion and Conclusions
The scarcity of conventional RIG prompted research and development of alternatives. Multiple
MAbs and their combinations have been evaluated in vitro and in vivo during the past decade as
potential replacements for RIG (e.g., SO57 [7]; CR57, CR4098, [8,9,12]; RAB1 [18]; E559.9.14, 1112-1,
62-71-3, M727-5-1, and M777-16-3 [19]; RVC20-RVC58 [3,10,20]).
A common denominator for all individual MAbs is their limited breadth of neutralization,
inevitably resulting in the inability of one MAb to neutralize the entire spectrum of RABV variants.
However, as previous in vivo experiments of [8,11] have demonstrated, this can be compensated by a
combination of two MAbs, which bind to non-overlapping epitopes.
Our study has shown that in cases of severe exposures to bat RABV (i.e., high virus doses
delivered intramuscularly), administration of either HRIG or CL184, is critical for rapid peripheral
neutralization and clearance of rabies virus. In both mock-control (placebo) and inactivated rabies
vaccine-only groups, the mortality of 62–100% was observed (Tables 3 and 4). In contrast, CL184,
when administered in a dose ≥6 µg/kg in combination with vaccine, provided a significant benefit
compared to vaccine alone.
In addition, the efficacy of CL184 plus vaccine in a dose ≥12 µg/kg was not inferior when
compared to PEP consisting of HRIG (20 IU/kg) and rabies vaccine (HDCV), with 50–67% of
experimental animals surviving a Ln RABV challenge, 48–57% surviving Ph RABV challenge, 95–100%
surviving Ef-w1 challenge, and 67–100% surviving a Tb RABV challenge (Table 4, Figure 3).
Importantly, our experiments have shown that CL184 is efficacious against challenge with Ph
RABV, which was not neutralized in vivo by the MAb CR4098, a component of the CL184 cocktail,
given the mutation I338T (Tables 1, 2 and 4; Figure 3). Of note, this mutation was introduced during
cell culture amplification of the primary Ph RABV isolate as indicated by G gene sequencing of a series
of virus stocks. Epitope mutations might result either from adaptation of the primary RABV isolates
to cell culture as shown in the case of south central skunk RABV (Rupprecht, Marissen, personal
communication). Alternatively, both sequence variants might be present in the original field isolate in
different proportions. Although initially described as a result of selection of CVS rabies strain mutants
following culture with neutralizing anti-glycoprotein antibodies [21], our study demonstrated that the
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I338T mutation affecting neutralization could also occur as a result of amplification in cell culture or
in the laboratory rodent model without antibody-mediated selection pressure. Of note, 338T did not
appear in consensus sequences of 10 natural Ph RABV isolates (data not shown). The Ph 3860 virus
with the predominant I338T substitution served as a good model to assess the in vivo efficacy of CL184
given that it was not neutralized in vitro by one of the cocktail MAbs.
Natural occurrence of RABV with mutation(s) in the MAb binding epitope is, however, critical
for the assessment of the adequacy of a particular MAb or cocktail of MAbs to be used as PEP in a
particular geographic area. Sequencing of epitopes has been shown to be a reliable predictor of MAb
neutralization capacity in vitro and in vivo. As previously described [13], the binding epitope for CR57
is relatively conserved with only one isolate/sequence exception (frequency 0.1%; 1/1042, Chinese
dog, SE Asia-2), the K226M substitution, shown to preclude binding (data not shown). However,
this reported mutation is more likely to be a sequence error rather than representing a true natural
isolate, as in more than 175 Chinese RABV isolates no critical mutation in the CR57 epitope was
observed (data not shown). Although the frequency of substitutions precluding neutralization of MAb
CR4098 in antigenic site III is higher (N336D, 63/1042, 6%, including besides others big brown bat
(Eptesicus fuscus) RABV from North America), our study showed that combining CR57 and CR4098 in a
cocktail can effectively neutralize virus in vivo even if one of those MAbs does not neutralize it in vitro.
Of note, CR4098 was still shown to bind to RABV glycoprotein harboring an N336D mutation [8]
which could facilitate viral clearance in vivo. In addition, in neutralization experiments using a natural
big brown bat (Eptesicus fuscus) RABV isolate harboring a N336D mutation, complete neutralization by
CR4098 at 15 µg/mL was observed (data not shown). Overall, these findings emphasize the importance
of WHO recommendations requiring inclusion of at least two MAbs [3] with non-overlapping epitopes
in biologics for PEP as well as a need for continuous surveillance for natural occurrence of RABV
isolates with mutations which may preclude MAb binding.
Although effective concentration of immune globulin in the circulation of individual experimental
animals was not measured during the observation period, mortality and survivorship data
demonstrated a dose effect, with lower Mab doses resulting in higher mortality.
Virulence of different RABV variants influences the efficacy of PEP. As demonstrated in this study,
viruses which are more pathogenic in a particular model (e.g., Tb RABV) and possibly spread more
rapidly towards the CNS, require an earlier initiation of PEP (2 hours p.i.) as compared to other viruses,
for which PEP initiated 6 or 24 h p.i. still seemed to provide an adequate prophylactic effect within
the hamster model (Table 4). Although pathogenesis is dependent on route, viral dose, host species
and proximity the exposure site to the CNS, further studies may elucidate differences in the kinetics of
peripheral neuronal entry and axonal spread of various RABVs.
In this study, the efficacy of CL184, when administered in a dose ≥12 µg/kg in combination
with a commercial inactivated rabies vaccine, was not inferior to PEP consisting of HRIG and the
same vaccine. As such, CL184 presents a promising, non-inferior alternative for RIG during rabies
PEP. Large scale and lower cost production of MAbs could ensure availability and affordability of
this critical life-saving biologic in rabies enzootic countries and would significantly contribute to the
reduction of human rabies deaths globally.
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